NCT05992870 Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction
| NCT ID | NCT05992870 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hubei Cancer Hospital |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-07-08 |
| Primary Completion | 2025-07-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-07-08 with a primary completion date of 2025-07-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neoadjuvant radiotherapy(NART) followed by mastectomy and immediate DIEP flap reconstruction is feasible and technically safe. However, reports of NACT followed immediate implant-based breast reconstruction are rare. Some studies have shown that NART followed immediate implant-based breast reconstruction seems feasible and can be safely attempted. It's well known that radiotherapy after implant-based breast reconstruction have negative effects on implant and cosmetic results. So, investigators conducted a polit study to learn about acute post-surgical complications following skin-sparing mastectomy and immediate implant-based breast reconstruction after NART.
Eligibility Criteria
Inclusion Criteria: Women \>18 years with histopathologically-confirmed breast cancer, who: * require mastectomy for any reason * a known indication for (adjuvant) radiotherapy * require implant-based breast reconstruction Exclusion Criteria: * Inability to give informed consent * MDT unable to make recommendation for radiotherapy based on pre-operative histopathological and imaging findings * Previous history of breast cancer or another malignancy for which radiotherapy of the breast or axilla * Pregnant or lactating * inflammatory breast cancer
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05992870 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05992870 currently recruiting?
Yes, NCT05992870 is actively recruiting participants. Contact the research team at 34053889@qq.com for enrollment information.
Where is the NCT05992870 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT05992870 clinical trial?
NCT05992870 is sponsored by Hubei Cancer Hospital. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.